SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 189 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $71,037 | -39.8% | 40,362 | +7.5% | 0.00% | 0.0% |
| Q4 2022 | $117,904 | -29.0% | 37,549 | +10.8% | 0.00% | -50.0% |
| Q3 2022 | $166,000 | +19.4% | 33,883 | +1.0% | 0.00% | +100.0% |
| Q2 2022 | $139,000 | -28.4% | 33,556 | +0.3% | 0.00% | -50.0% |
| Q1 2022 | $194,000 | -22.1% | 33,471 | +0.7% | 0.00% | 0.0% |
| Q4 2021 | $249,000 | -17.0% | 33,249 | -0.2% | 0.00% | 0.0% |
| Q3 2021 | $300,000 | -24.2% | 33,313 | +0.6% | 0.00% | -33.3% |
| Q2 2021 | $396,000 | -9.8% | 33,099 | -5.4% | 0.00% | -25.0% |
| Q1 2021 | $439,000 | -19.2% | 34,998 | +0.7% | 0.00% | -20.0% |
| Q4 2020 | $543,000 | +59.2% | 34,770 | -3.8% | 0.01% | +66.7% |
| Q3 2020 | $341,000 | +45.7% | 36,132 | +38.1% | 0.00% | 0.0% |
| Q2 2020 | $234,000 | +35.3% | 26,168 | -3.9% | 0.00% | 0.0% |
| Q1 2020 | $173,000 | – | 27,218 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |